Official ESCRS | European Society of Cataract & Refractive Surgeons
Lisbon 2017 Delegate Registration Programme Exhibition Virtual Exhibition Satellites OneWorld Travel Discount
escrs app advert

Effect of an opaque annular inlay embedded in an IOL on the ability to use retinal diagnostic and imaging devices

Search Title by author or title

Session Details

Session Title: Pseudophakic IOLs: Enlarged Depth of Focus

Session Date/Time: Tuesday 10/10/2017 | 08:30-10:30

Paper Time: 09:38

Venue: Room 3.1

First Author: : A. Saad AUSTRIA

Co Author(s): :    W. Riha                    

Abstract Details


The IC-8™ IOL (AcuFocus, Irvine, CA), is a hydrophobic acrylic IOL with an integrated opaque annulus (diameter 3.8mm) forming a central aperture of 1,36mm to extend depth of focus. It is placed monocularly in the non-dominant eye. This study examines whether the opaque annulus of the IOL interferes with retinal imaging or glaucoma diagnostic devices.


Augenzentrum Aus der Au, Fribourg, CH, Rothschild Foundation, Paris, FR


Retinal diagnostic devices included fundus imaging as well as OCT. The Digital Wide Field (Volk Optical Inc, Ohio, US), the Ultra-Widefield Imaging 200Tx device (Optos plc, UK) and the RS-3000 OCT (Nidek CO, Ltd, Japan) , Glaucoma detecting devices was the Humphrey® Field Analyzer/HFA II (Carl Zeiss Meditec, Jena, Germany)


There were no devices that could not be used to obtain usable images for diagnostic purposes. All retinal quadrants could be examined well with the Digital Wide Field lens with dilated pupil. Fundus images from the Ultra-Widefield-device were darker as expected but of sufficient quality. OCT results of the macula as well as of the optic disc were of good quality, similar compared to images done in small pupil size eyes. Data of a series of patients will be presented at the meeting.


Although this is a small preliminary study, it suggests that implantation of the IC-8™ IOL will not interfere significantly with the imaging and examination of ocular structures.

Financial Disclosure:

travel has been funded, fully or partially, by a company producing, developing or supplying the product or procedure presented

Back to previous